NEO
Overvalued by 186.8% based on the discounted cash flow analysis.
Market cap | $1.91 Billion |
---|---|
Enterprise Value | $2.07 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-0.67 |
Beta | 1.78 |
Outstanding Shares | 127,711,930 |
Avg 30 Day Volume | 895,517 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -22.73 |
---|---|
PEG | 187.44 |
Price to Sales | 3.7 |
Price to Book Ratio | 2.11 |
Enterprise Value to Revenue | 3.39 |
Enterprise Value to EBIT | -21.91 |
Enterprise Value to Net Income | -25 |
Total Debt to Enterprise | 0.26 |
Debt to Equity | 0.58 |
No data
No data
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...